Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dose 1 BD Clear all
Completed Phase 1Phase 2 Interventional Results available

Nutrition, Exercise, and Wellness Treatment (NEW Tx) for Bipolar Disorder

NCT01615367
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Nutrition, Exercise, and Wellness (NEW) psychotherapy, Typically consists of at least one FDA-approved mood stabilizer
Other · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Sep 24, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

NCT01991795
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Ticagrelor 60 mg, Ticagrelor placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 130 Years
Enrollment
19,271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
295
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 238 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 24, 2026, 11:02 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

NCT04224493
View directory record Official record
Conditions
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions
Tazemetostat, Placebo oral tablet, Lenalidomide, Rituximab
Drug · Combination Product
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
57
States / cities
Mobile, Alabama • Tucson, Arizona • Cerritos, California + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 24, 2026, 11:02 AM EDT
Active, not recruiting Phase 1 Interventional

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

NCT02143466
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer
Interventions
Part A - AZD9291 in combination with AZD6094, Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects), Part A - AZD9291 in combination with intermittent selumetinib, Part A - AZD9291 in combination with MEDI4736, Part B - AZD9291 in combination with AZD6094, Part B - AZD9291 in combination with selumetinib, Part B - AZD9291 in combination with MEDI4736, Part C - AZD6094 monotherapy (Japan only), Part C - AZD9291 in combination with AZD6094 (Japan only), Part D - AZD9291 in combination with AZD6094
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
6
States / cities
Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 24, 2026, 11:02 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

NCT04796896
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo, mRNA-1273.214
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
6 Months to 11 Years
Enrollment
11,942 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 24, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Comparison of Delivery Routes of Flu Vaccine in Adults

NCT00170547
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
1,597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
10
States / cities
Stanford, California • Torrance, California • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Sep 24, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Gentamicin Bladder Instillation in Individuals With Spinal Cord Injury Having Chronic Urinary Tract Infections

NCT03931408
View directory record Official record
Conditions
Neurogenic Bladder, Spinal Cord Injuries
Interventions
Gentamicin Sulfate, Placebo instillation (saline alone), No instillation
Drug · Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 24, 2026, 11:02 AM EDT
Completed Phase 4 Interventional Results available

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

NCT02794480
View directory record Official record
Conditions
Asthma
Interventions
ELLIPTA DPI, GSK MDI, AZ MDI
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Huntington Beach, California • Aventura, Florida • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 24, 2026, 11:02 AM EDT
Completed Phase 4 Interventional Results available

CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)

NCT03408873
View directory record Official record
Conditions
Bipolar Disorder, Medication Adherence, Medication Non Adherence
Interventions
Abilify Maintena, Customized Adherence Enhancement (CAE)
Drug · Behavioral
Lead sponsor
Martha Sajatovic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Sep 24, 2026, 11:02 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

NCT04493853
View directory record Official record
Conditions
Hormone-Sensitive Prostate Cancer
Interventions
Capivasertib, Placebo, Abiraterone Acetate
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Tucson, Arizona • La Jolla, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 24, 2026, 11:02 AM EDT
Completed Phase 4 Interventional Results available

Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects

NCT00517634
View directory record Official record
Conditions
Asthma
Interventions
FP, SFC, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 24, 2026, 11:02 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

NCT03334617
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Danvatirsen, Ceralasertib, Vistusertib, Olaparib, Oleclumab, Trastuzumab deruxtecan, Cediranib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
17
States / cities
Duarte, California • Fullerton, California • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 24, 2026, 11:02 AM EDT
Not yet recruiting Phase 2 Interventional

Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO)

NCT06712433
View directory record Official record
Conditions
Sarcoma,Soft Tissue
Interventions
2% intranasal mupirocin ointment, 4% chlorhexidine gluconate body cleanser
Drug
Lead sponsor
Adam Olson
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 24, 2026, 11:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants

NCT07215078
View directory record Official record
Conditions
Healthy Volunteer
Interventions
atirmociclib (PF-07220060)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 24, 2026, 11:02 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

NCT01933932
View directory record Official record
Conditions
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions
Selumetinib, Docetaxel, Placebo, Pegylated G-CSF
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
17
States / cities
Aurora, Colorado • Pembroke Pines, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 24, 2026, 11:02 AM EDT
Completed Phase 1 Interventional Results available

Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe

NCT01890473
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Huntsville, Alabama • Centennial, Colorado • Daytona Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Sep 24, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

NCT00391872
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
18,624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
139
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Sep 24, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study in Subjects With Asthma

NCT00980200
View directory record Official record
Conditions
Asthma
Interventions
Dose 4 QD, Dose 3 QD, placebo, Dose 2 QD, Dose 1 BD
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Cypress, California • Huntington Beach, California • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 24, 2026, 11:02 AM EDT